- Home
- AEMD vs SXTP Comparison
AEMD vs SXTP Comparison
Compare AEMD & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEMD | SXTP |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | AEMD | SXTP |
|---|---|---|
| Price | $3.17 | $4.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $287.50 | $17.60 |
| AVG Volume (30 Days) | 70.4K | ★ 10.1M |
| Earning Date | 02-11-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,364,945.00 |
| Revenue This Year | N/A | $146.28 |
| Revenue Next Year | N/A | $24.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 202.10 |
| 52 Week Low | $2.22 | $1.36 |
| 52 Week High | $64.00 | $24.00 |
Technical Indicators
Market Signals| Indicator | AEMD | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 85.16 |
| Support Level | $2.64 | $1.86 |
| Resistance Level | $3.19 | $8.62 |
| Average True Range (ATR) | 0.30 | 0.48 |
| MACD | 0.10 | 0.48 |
| Stochastic Oscillator | 87.96 | 51.21 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.